Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F.
Morganti S, et al. Among authors: stokes s.
NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8.
NPJ Breast Cancer. 2024.
PMID: 38627457
Free PMC article.